If these results are validated, PI3K/AKT pathway mutations may be used in the future to select tumors at risk for treatment failure using standard chemoradiation (pelvic irradiation and concurrent administration of cisplatin chemotherapy).Our results suggest that AKT inhibitors could improve response to chemoradiation in cervical cancer for appropriately selected patients. The gene discussed is PIK3CA; the disease is cervical cancer.